Source comparison
PT-141 for Sexual Health Research Evidence: Dosing Comparison
Premenopausal FSIAD 1.75mg Subcutaneous +0.3–0.5 FSFI desire score; 25% response rate Nausea 40%, flushing 20% Phase 3 RCT (JAMA 2019) Male ED (mild-moderate) 2.0mg 64% vs 23% erection success Nausea 35%, headache 15% Phase 2 crossover (2007) Postmenopausal ar
This comparison does not assign a generated winner or score.
- Premenopausal FSIAD
- 1.75mg
- Subcutaneous
- +0.3–0.5 FSFI desire score; 25% response rate
- Nausea 40%, flushing 20%
- Phase 3 RCT (JAMA 2019)
- Male ED (mild-moderate)
- 2.0mg
- 64% vs 23% erection success
- Nausea 35%, headache 15%
- Phase 2 crossover (2007)
- Postmenopausal arousal disorder
- Non-significant improvement
- Nausea 38%, BP elevation
- Phase 2 (J Sex Med)
- Hypoactive desire (mixed gender)
- 0.75–2.0mg
- Intranasal (discontinued)
- Variable; hypertensive crises in 1–2% led to discontinuation
- Severe hypertension, rhinitis
- Phase 2 (discontinued route)